GlassScriptPhysician profile
Ziad Khoury
NPI 1285075218
$7,069.11
in general payments reported to CMS, 2019-2025
26 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $346 · 2021: $218 · 2022: $676 · 2023: $1,174 · 2024: $2,041 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,823 · Consulting Fee: $704 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.01 |
| Consulting Fee | $704.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Education | $126.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $716.70 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $697.86 | 2024-2025 | |
| Travere Therapeutics, INC. | $653.48 | 2023-2025 | |
| Vifor Pharma, INC. | $646.43 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $611.66 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $487.01 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Becton, Dickinson and Company | $392.50 | 2022-2024 | |
| Ardelyx, INC. | $387.84 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $366.65 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $271.20 | 2019-2025 | Velphoro, Velphoro |
| Lilly USA, LLC | $262.67 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $228.64 | 2019-2024 | Vafseo, Auryxia |
| Novo Nordisk INC | $165.05 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Calliditas Therapeutics US INC. | $156.75 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $138.35 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $136.43 | 2022-2025 | Lupkynis |
| Sentynl Therapeutics, INC. | $129.00 | 2020 | |
| Glaxosmithkline, LLC. | $127.34 | 2022-2025 | Jesduvroq, Benlysta |
| Horizon Therapeutics Plc | $117.36 | 2022-2023 | Krystexxa |
| Baxter Healthcare | $101.91 | 2019 | |
| Zoll Medical Corporation | $91.67 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.62 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $33.51 | 2025 | |
| Alexion Pharmaceuticals, INC. | $29.92 | 2023 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $29.39 | 2025 | Givlaari |
| Nxstage Medical, INC. | $18.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Khoury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.